NCT01835223View on ClinicalTrials.gov

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 11, 2013

Primary Completion Date

December 24, 2018

Study Completion Date

November 8, 2019

Conditions
Advanced Adult Hepatocellular CarcinomaNon-Resectable Hepatocellular Carcinoma
Interventions
DRUG

Tivozanib (1mg)

Given PO

DRUG

Tivozanib (1.5mg)

Given PO

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

44106

Case Western Reserve University, Cleveland

Sponsors
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

AVEO Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER